2348 Stock Overview
An investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Dawnrays Pharmaceutical (Holdings) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.21 |
| 52 Week High | HK$1.40 |
| 52 Week Low | HK$1.00 |
| Beta | 0.68 |
| 1 Month Change | -1.63% |
| 3 Month Change | 9.01% |
| 1 Year Change | 18.63% |
| 3 Year Change | -25.31% |
| 5 Year Change | -14.79% |
| Change since IPO | 191.57% |
Recent News & Updates
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem
Sep 21
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015
Sep 11Recent updates
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem
Sep 21Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015
Sep 11Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065
May 25Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065
Apr 22Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065
Apr 08Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065
Mar 25Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015
Aug 30Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year
May 26Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073
Apr 04Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015
Sep 19Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals
Sep 22Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015
Sep 12Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015
Aug 29Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend
Feb 28Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?
Feb 07
Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares
Jan 14Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Dec 22What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?
Dec 09Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend
Nov 23Shareholder Returns
| 2348 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 2.5% | -1.9% | -0.5% |
| 1Y | 18.6% | -3.9% | 19.9% |
Return vs Industry: 2348 exceeded the Hong Kong Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: 2348 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 2348 volatility | |
|---|---|
| 2348 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 2348 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2348's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,175 | Liwei Yu | www.dawnrays.com |
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics.
Dawnrays Pharmaceutical (Holdings) Limited Fundamentals Summary
| 2348 fundamental statistics | |
|---|---|
| Market cap | HK$1.82b |
| Earnings (TTM) | HK$600.12m |
| Revenue (TTM) | HK$1.15b |
3.0x
P/E Ratio1.6x
P/S RatioIs 2348 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2348 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.08b |
| Cost of Revenue | CN¥493.89m |
| Gross Profit | CN¥584.78m |
| Other Expenses | CN¥21.68m |
| Earnings | CN¥563.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.37 |
| Gross Margin | 54.21% |
| Net Profit Margin | 52.20% |
| Debt/Equity Ratio | 5.6% |
How did 2348 perform over the long term?
See historical performance and comparisonDividends
6.4%
Current Dividend Yield19%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 07:05 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dawnrays Pharmaceutical (Holdings) Limited is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Mulcahy | AMC Wanhai Securities Ltd. |
| Wing-Tai Ng | China Galaxy International Securities (Hong Kong) |
| Wai Chak Yuen | Cinda International Research Limited |